RecruitingPhase 2NCT05190991

Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever

Studying Familial Mediterranean fever

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
R-Pharm International, LLC
Principal Investigator
Mikhail Samsonov
R-Pharm
Intervention
RPH-104(biological)
Enrollment
60 enrolled
Eligibility
18-80 years · All sexes
Timeline
20212029

Study locations (8)

Collaborators

Atlant Clinical LLC · Unimed Laboratories · Data Management 365 · R-Pharm JSC · TRPharm İlaç Sanayi Ticaret Anonim Şirketi and ASCOT SCIENCE Education and Consulting Ltd. · Exacte Labs LLC · Key Stat LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05190991 on ClinicalTrials.gov

Other trials for Familial Mediterranean fever

Additional recruiting or active studies for the same condition.

See all trials for Familial Mediterranean fever

← Back to all trials